By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Wellstat Therapeutics Corporation 

930 Clopper Road

Gaithersburg  Maryland  20878  U.S.A.
Phone: 240-631-2500 Fax: 240-683-3793


Company News
Wellstat Therapeutics Corporation’ New Drug Application For Uridine Triacetate As Antidote To Overexposure To Chemotherapy Drug 5-Fluorouracil (5-FU) Accepted For Review By FDA 9/10/2015 9:57:27 AM
Almac Group’s Integrated CMC Services Support US Approval Of Wellstat Therapeutics Corporation’ First Commercial Orphan Drug Product 9/9/2015 9:14:20 AM
Wellstat Therapeutics Corporation Announces FDA Approval Of XURIDEN To Treat Rare Pediatric Disorder Hereditary Orotic Aciduria (HOA) 9/8/2015 11:05:42 AM
Wellstat Therapeutics Corporation Grants BTG plc (BGC.L) European Distribution Rights to Investigational Antidote for 5-FU Overexposure 5/22/2012 12:20:31 PM
Wellstat Therapeutics Corporation Grants U.S. Distribution Rights to its Investigational Antidote for 5-FU Overexposure to Specialist Healthcare Company BTG plc (BGC.L) 7/6/2011 11:07:40 AM
Wellstat Therapeutics Corporation Investigational Drug Shows Life-Saving Potential In Treating Toxicity Of Widely Used Cancer Chemotherapy 5/22/2010 12:27:35 PM
Sanofi (France) (SAN.PA) Buys Wellstat Therapeutics Corporation's Type II Diabetes Drug PN2034 For Up To $350 Million 10/21/2009 6:47:27 AM
Wellstat Therapeutics Corporation's Chemotherapy Antidote May Be Lifesaving 5/19/2009 6:56:23 AM
Wellstat Therapeutics Corporation Release: Investigational Drug Shows Promise as Treatment for Overexposure to Common Cancer Chemotherapy 5/15/2009 10:39:24 AM